$CARM
Carisma Therapeutics Inc. Stock $carm

$carm Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000148500315000015 Filed on November 04, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q3
Revenue	$565.0K	$67.00K	$539.0K
YoY Change	50.67%	-87.57%	-13.34%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.320M	$2.680M	$2.270M
YoY Change	4.98%	18.06%	187.34%
% of Gross Profit
Research & Development	$8.080M	$6.745M	$8.872M
YoY Change	53.61%	-23.97%	162.8%
% of Gross Profit
Depreciation & Amortization	$80.00K	$100.0K	$100.0K
YoY Change	-20.0%	0.0%	-9.09%
% of Gross Profit
Operating Expenses	$10.40M	$9.426M	$11.14M
YoY Change	39.26%	-15.39%	167.68%
Operating Profit	-$9.838M	-$9.359M	-$10.60M
YoY Change	38.66%	-11.72%	199.49%
Interest Expense	-$420.0K	-$407.0K	-$74.00K
YoY Change	200.0%	450.0%	-74.39%
% of Operating Profit
Other Income/Expense, Net	-$70.00K	-$334.0K	-$72.00K
YoY Change	-92.31%	363.89%	-73.63%
Pretax Income	-$10.33M	-$9.690M	-$10.67M
YoY Change	26.9%	-9.18%	180.05%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$10.33M	-$9.693M	-$10.67M
YoY Change	26.91%	-9.19%	179.94%
Net Earnings / Revenue	-1828.14%	-14467.16%	-1980.33%
Basic Earnings Per Share		-$0.50
Diluted Earnings Per Share	-$528.4K	-$0.50	-$662.7K
COMMON SHARES
Basic Shares Outstanding	19.59M shares	19.35M shares	16.27M shares
Diluted Shares Outstanding		19.35M shares

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$36.10M	$46.40M	$35.90M
YoY Change	-33.27%	29.25%	820.51%
Cash & Equivalents	$36.08M	$46.36M	$35.94M
Short-Term Investments
Other Short-Term Assets	$200.0K	$700.0K	$300.0K
YoY Change	-33.33%	133.33%	50.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$36.31M	$47.02M	$36.29M
YoY Change	-33.25%	29.55%	764.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$407.0K	$480.0K	$585.0K
YoY Change	-16.26%	-17.95%	-35.0%
Goodwill	$0.00
YoY Change
Intangibles	$0.00
YoY Change
Long-Term Investments
YoY Change
Other Assets	$13.00K	$14.00K	$11.00K
YoY Change	-31.58%	27.27%
Total Long-Term Assets	$514.0K	$588.0K	$690.0K
YoY Change	-14.19%	-14.78%	-23.33%
TOTAL ASSETS
Total Short-Term Assets	$36.31M	$47.02M	$36.29M
Total Long-Term Assets	$514.0K	$588.0K	$690.0K
Total Assets	$36.83M	$47.60M	$36.98M
YoY Change	-33.05%	28.72%	625.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.246M	$2.279M	$2.588M
YoY Change	-49.31%	-11.94%	269.71%
Accrued Expenses	$1.794M	$1.146M	$1.656M
YoY Change	-9.71%	-30.8%	452.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$4.100M	$3.700M	$1.600M
YoY Change	1266.67%	131.25%	-5.88%
Total Short-Term Liabilities	$7.580M	$7.607M	$6.507M
YoY Change	45.71%	16.9%	-8.35%
LONG-TERM LIABILITIES
Long-Term Debt	$9.800M	$11.00M	$1.600M
YoY Change	1.03%	587.5%	-51.52%
Other Long-Term Liabilities	$423.0K	$275.0K	$100.0K
YoY Change	10475.0%	175.0%	-87.5%
Total Long-Term Liabilities	$423.0K	$275.0K	$1.700M
YoY Change	10475.0%	-83.82%	-58.54%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.580M	$7.607M	$6.507M
Total Long-Term Liabilities	$423.0K	$275.0K	$1.700M
Total Liabilities	$8.003M	$7.882M	$8.200M
YoY Change	53.73%	-3.88%	-26.79%
SHAREHOLDERS EQUITY
Retained Earnings	-$125.2M	-$114.9M	-$83.61M
YoY Change	36.46%	37.39%
Common Stock	$20.00K	$20.00K	$16.00K
YoY Change	11.11%	25.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$18.94M	$28.67M	$28.78M
YoY Change
Total Liabilities & Shareholders Equity	$36.83M	$47.60M	$36.98M
YoY Change	-33.05%	28.72%	625.12%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q3
OPERATING ACTIVITIES
Net Income	-$10.33M	-$9.693M	-$10.67M
YoY Change	26.91%	-9.19%	179.94%
Depreciation, Depletion And Amortization	$80.00K	$100.0K	$100.0K
YoY Change	-20.0%	0.0%	-9.09%
Cash From Operating Activities	-$9.380M	-$7.640M	-$8.690M
YoY Change	31.37%	-12.08%	173.27%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	-$10.00K
YoY Change		-100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$10.00K
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-900.0K	510.0K	-390.0K
YoY Change	-103.56%	-230.77%	3800.0%
NET CHANGE
Cash From Operating Activities	-9.380M	-7.640M	-8.690M
Cash From Investing Activities	0.000	0.000	-10.00K
Cash From Financing Activities	-900.0K	510.0K	-390.0K
Net Change In Cash	-10.28M	-7.130M	-9.090M
YoY Change	-156.76%	-21.56%	184.95%
FREE CASH FLOW
Cash From Operating Activities	-$9.380M	-$7.640M	-$8.690M
Capital Expenditures	$0.00	$0.00	-$10.00K
Free Cash Flow	-$9.380M	-$7.640M	-$8.680M
YoY Change	31.37%	-11.98%	172.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001485003
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14000	shares
	ebio	Fair Value Assets Liabilities Transfer Between Levels FairValueAssetsLiabilitiesTransferBetweenLevels	0	USD
	ebio	Research Term ResearchTerm	P30Y
	us-gaap	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1 NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1	0	shares
	us-gaap	Noncash Or Part Noncash Acquisition Noncash Financial Or Equity Instrument Consideration Warrants Issued1 NoncashOrPartNoncashAcquisitionNoncashFinancialOrEquityInstrumentConsiderationWarrantsIssued1	328000	shares
	ebio	Shareholders Equity Note Brokers Fee Percentageof Gross Proceeds ShareholdersEquityNoteBrokersFeePercentageofGrossProceeds	0.03
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.23
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	19587277	shares
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Eleven Biotherapeutics, Inc.
	dei	Trading Symbol TradingSymbol	EBIO
	ebio	Change In Fair Value Of Preferred Stock Warrants ChangeInFairValueOfPreferredStockWarrants	3186000	USD
	ebio	Collaborative Arrangement Date Of Agreement CollaborativeArrangementDateOfAgreement	2013-05-28
	ebio	Conversion Of Preferred Stock Into Common Stock ConversionOfPreferredStockIntoCommonStock	56678000	USD
	ebio	Conversion Of Preferred Stock Into Common Stock ConversionOfPreferredStockIntoCommonStock	0	USD
	ebio	Conversion Of Preferred Stock Warrant To Common Stocks Warrants ConversionOfPreferredStockWarrantToCommonStocksWarrants	247000	USD
	ebio	Conversion Of Preferred Stock Warrant To Common Stocks Warrants ConversionOfPreferredStockWarrantToCommonStocksWarrants	0	USD
CY2015Q3	ebio	Estimated Milestone Payment To Be Received EstimatedMilestonePaymentToBeReceived	25000000	USD
CY2015Q3	ebio	Fair Value Assets Liabilities Transfer Between Levels FairValueAssetsLiabilitiesTransferBetweenLevels	0	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2458000	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	2279000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1987000	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1146000	USD
CY2014Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	195000	USD
CY2015Q3	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	199000	USD
CY2014Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	128558000	USD
CY2015Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	143518000	USD
CY2014Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	272000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	293000	USD
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	0	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1645709	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3129496	shares
CY2014Q4	us-gaap	Assets Assets	55000000	USD
CY2015Q3	us-gaap	Assets Assets	47603000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	54401000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	47015000	USD
CY2014Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	54059000	USD
CY2015Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	46362000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7942000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	35943000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54059000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46362000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	28001000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7697000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19538510	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	17933260	shares
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	17933260	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19538510	shares
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	20000	USD
CY2014Q4	us-gaap	Construction Payable Current ConstructionPayableCurrent	834000	USD
CY2015Q3	us-gaap	Construction Payable Current ConstructionPayableCurrent	410000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	506000	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	471000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	311000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	292000	USD
CY2014Q4	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	3219000	USD
CY2015Q3	us-gaap	Derivative Fair Value Of Derivative Liability DerivativeFairValueOfDerivativeLiability	33000	USD
CY2014Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3219000	USD
CY2015Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	33000	USD
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.66
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1901.68
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.50
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	874000	USD
CY2015Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	436000	USD
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	4800000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y5M23D
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	400000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-50000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-3186000	USD
CY2014	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.0000
	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0.0000
CY2014	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P2Y11M1D
	us-gaap	Fair Value Assumptions Expected Term FairValueAssumptionsExpectedTerm	P2Y2M1D
CY2014	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.5679
	us-gaap	Fair Value Assumptions Expected Volatility Rate FairValueAssumptionsExpectedVolatilityRate	0.6005
CY2014	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0110
	us-gaap	Fair Value Assumptions Risk Free Interest Rate FairValueAssumptionsRiskFreeInterestRate	0.0064
CY2014Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2269000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6259000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2681000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7531000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1692000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-179000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	984000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-568000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-804000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-35000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	258000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	311000	USD
CY2014Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-74000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-237000	USD
CY2015Q3	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-407000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	50307000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	17737000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-137000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-286000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-22169000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-972000	USD
	us-gaap	Interest Paid InterestPaid	177000	USD
	us-gaap	Interest Paid InterestPaid	644000	USD
CY2014Q4	us-gaap	Interest Payable Current InterestPayableCurrent	84000	USD
CY2015Q3	us-gaap	Interest Payable Current InterestPayableCurrent	88000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	55000000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	47603000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	5202000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7607000	USD
CY2014Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	3219000	USD
CY2015Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	33000	USD
CY2014Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	9749000	USD
CY2015Q3	us-gaap	Long Term Notes Payable LongTermNotesPayable	11023000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-25148000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-10674000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-26017000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-9693000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-23123000	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10674000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-26536000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9693000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-23123000	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-72000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-181000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-334000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2235000	USD
CY2014Q4	us-gaap	Notes Payable Current NotesPayableCurrent	251000	USD
CY2015Q3	us-gaap	Notes Payable Current NotesPayableCurrent	3711000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	11141000	USD
	us-gaap	Operating Expenses OperatingExpenses	27704000	USD
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	9426000	USD
	us-gaap	Operating Expenses OperatingExpenses	25783000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-10602000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25836000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-9359000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-25358000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	0	USD
CY2015Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13000	USD
CY2014Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	19000	USD
CY2015Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	14000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4000	USD
CY2015Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	275000	USD
CY2014Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	56000	USD
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	73000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3207000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	28000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	67000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	137000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	286000	USD
CY2014Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	519000	USD
CY2015Q3	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	0	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	342000	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	653000	USD
	us-gaap	Proceeds From Collaborators ProceedsFromCollaborators	1750000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	51505000	USD
CY2014Q3	us-gaap	Revenues Revenues	539000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	12675000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	5000000	USD
	us-gaap	Proceeds From Royalties Received ProceedsFromRoyaltiesReceived	0	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	51000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	62000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	486000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	480000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1249000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8872000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21445000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6745000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18252000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	94000	USD
CY2015Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	94000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-91750000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-114873000	USD
	us-gaap	Revenues Revenues	1868000	USD
CY2015Q3	us-gaap	Revenues Revenues	67000	USD
	us-gaap	Revenues Revenues	425000	USD
CY2014Q3	us-gaap	Share Based Compensation ShareBasedCompensation	808000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1945000	USD
CY2015Q3	us-gaap	Share Based Compensation ShareBasedCompensation	629000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1895000	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	828209	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.96
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	230318	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	799828	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1438528	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1932489	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.93
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.19
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1637621	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.67
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.77
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	8.79
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	8.69
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y3M11D
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M10D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y10M28D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y1M17D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	75549	shares
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	36826000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	28665000	USD
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16098000	shares
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	19345000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	18806000	shares

Files In Submission

Name	View Source	Status
0001485003-15-000015-index-headers.html	Edgar Link	pending
0001485003-15-000015-index.html	Edgar Link	pending
0001485003-15-000015.txt	Edgar Link	pending
0001485003-15-000015-xbrl.zip	Edgar Link	pending
ebio-093015x10q.htm	Edgar Link	pending
ebio-093015x311.htm	Edgar Link	pending
ebio-093015x312.htm	Edgar Link	pending
ebio-093015x321.htm	Edgar Link	pending
ebio-20150930.xml	Edgar Link	completed
ebio-20150930.xsd	Edgar Link	pending
ebio-20150930_cal.xml	Edgar Link	unprocessable
ebio-20150930_def.xml	Edgar Link	unprocessable
ebio-20150930_lab.xml	Edgar Link	unprocessable
ebio-20150930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CARM
Carisma Therapeutics Inc. Stock $carm

2015 Q4 Form 10-Q Financial Statement

#000148500315000015 Filed on November 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CARM Carisma Therapeutics Inc. Stock $carm

2015 Q4 Form 10-Q Financial Statement

#000148500315000015 Filed on November 04, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CARM
Carisma Therapeutics Inc. Stock $carm